Business
Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution
Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide
About this update from Plus Therapeutics, Inc.
[{"type":"text","content":"Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide adoption and long-term commercialization strategy for REYOBIQ™\nHOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the appointment of Randy H. Goodman, Ph.D., M.H.A., as Vice President, Value Strategy & Health Economics and Outcomes Research (HEOR), effective April 13th, 2026. Dr. Goodman is a highly experienced health economics and market access leader with more than 20 years of experience spanning global pricing and reimbursement strategy, real-world evidence generation, and value-based healthcare modeling across the biotechnology, pharmaceutical, diagnostics, and medical device sectors. He has led the development of payer engagement strategies, health technology assessment (HTA) dossiers, and value frameworks supporting product launches and commercialization for leading healthcare organizations. “Randy brings a rare combination of deep HEOR expertise, payer strategy experience, and health policy insight that will be critical as we continue to expand access and adoption of CNSide and advance our therapeutic pipeline,” said Marc Hedrick, M.D., MBA, Plus Therapeutics President and Chief Executive Officer. “His leadership will strengthen our ability to clearly demonstrate the clinical and economic value of our technologies to payers, providers, and policymakers.” Dr. Goodman has advised leading global healthcare organizations, including Pfizer, Gilead Sciences, and Moderna, and has worked closely with government agencies such as the Centers for Medicare & Medicaid Services on value-based pricing and reimbursement frameworks. He has also served as a healthcare policy advisor to the White House on multiple health reform initiatives, contributing to the development of reimbursement and access frameworks at both the federal and state levels. In his new role, Dr. Goodman will lead Plus’ value strategy, HEOR, and market access initiatives, with a focus on supporting the continued commercial expansion of CNSide Diagnostics and establishing the evidence and reimbursement foundat...